<DOC>
	<DOCNO>NCT00004180</DOCNO>
	<brief_summary>RATIONALE : Rosiglitazone may help liposarcoma cell develop normal fat cell . PURPOSE : Phase II trial study effectiveness rosiglitazone treat patient liposarcoma .</brief_summary>
	<brief_title>Rosiglitazone Treating Patients With Liposarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine clinical activity rosiglitazone patient liposarcoma . - Assess impact regimen marker tumor proliferation differentiation status patient use biologic biochemical test correlative imaging . - Determine tolerance safety regimen patient . OUTLINE : Patients stratify histologic subtype ( well differentiate v dedifferentiate v myxoid/round cell v pleomorphic ) . Patients receive oral rosiglitazone twice daily . Treatment continue absence disease progression unacceptable toxicity . Patients follow 1-3 week every 3 month thereafter . PROJECTED ACCRUAL : A total 56-120 patient ( 14-30 per stratum ) accrue study within 15 month .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Liposarcoma</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven liposarcoma incurable standard multimodality approach ( e.g. , surgery and/or radiotherapy and/or chemotherapy ) Well differentiate OR Dedifferentiated OR Myxoid/round cell OR Pleomorphic Measurable disease No clinically unstable brain metastases No progression prior troglitazone therapy liposarcoma PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 1,000/mm3 Platelet count least 90,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL SGOT le 5 time upper limit normal Renal : Creatinine great 2.4 mg/dL Cardiovascular : No poorly control atrial arrhythmia , symptomatic angina pectoris , myocardial infarction within past 4 month No symptomatic congestive heart failure , percutaneous transluminal coronary angioplasty , coronary artery bypass graft within past 3 month Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception Oral contraceptive consider effective contraception No active retroviral disease No condition would preclude informed consent PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Prior chemotherapy allow recovered No concurrent cytotoxic therapy Endocrine therapy : No concurrent hormonal therapy Radiotherapy : See Disease Characteristics Prior radiotherapy allow recover At least 6 month since prior radiotherapy sole site measurable disease Concurrent localize radiotherapy single site disease allow sit measurable disease Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>adult liposarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
</DOC>